Concepedia

Lawrence de Garavilla

LD

48

Publications

2K

Citations

24

H-Index

1984

Active since

Affiliations

Johnson & Johnson (United States)(Current)

Springhouse

Einstein Medical Center Philadelphia

Robert Wood Johnson University Hospital

South College

Lawrence de Garavilla is an author at Johnson & Johnson (United States) specializing in medicine, pharmacology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

1984–2018

48

Publications

48

Cardiovascular Responses Mediated by Protease-Activated Receptor-2 (PAR-2) and Thrombin Receptor (PAR-1) are Distinguished in Mice Deficient in PAR-2 or PAR-1

Bruce P. Damiano, Wai Cheung, Rosemary J. Santulli et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 182 citations

Agonists of proteinase‐activated receptor 1 induce plasma extravasation by a neurogenic mechanism

Lawrence de Garavilla, Nathalie Vergnolle, Steven H. Young et al. · British Journal of Pharmacology · 2001 · 140 citations · Full text

Administration of a Potent Antagonist of Protease-Activated Receptor-1 (PAR-1) Attenuates Vascular Restenosis Following Balloon Angioplasty in Rats

Patricia Andrade‐Gordon, Claudia K. Derian, Bruce E. Maryanoff et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 112 citations

Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney

Andrew Y. Zhang, Yafei Chen, David X. Zhang et al. · American Journal of Physiology-Renal Physiology · 2003 · 102 citations

A Novel, Potent Dual Inhibitor of the Leukocyte Proteases Cathepsin G and Chymase

Lawrence de Garavilla, Michael N. Greco, N. Sukumar et al. · Journal of Biological Chemistry · 2005 · 92 citations · Full text

, , +17

Rows per page

1–5 of 48